Crossmark

Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates

Crossref DOI link: https://doi.org/10.1038/s41423-021-00809-2

Published Online: 2022-01-05

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pillet, Stéphane

Arunachalam, Prabhu S.

Andreani, Guadalupe

Golden, Nadia

Fontenot, Jane

Aye, Pyone Pyone

Röltgen, Katharina

Lehmicke, Gabrielle

Gobeil, Philipe

Dubé, Charlotte

Trépanier, Sonia

Charland, Nathalie

D’Aoust, Marc-André

Russell-Lodrigue, Kasi

Monjure, Christopher

Blair, Robert V.

Boyd, Scott D.

Bohm, Rudolf P.

Rappaport, Jay

Villinger, François

Landry, Nathalie

Pulendran, Bali https://orcid.org/0000-0001-6517-4333
Ward, Brian J.
License Information

Text and Data Mining valid from 2022-01-05

Version of Record valid from 2022-01-05
More Information

Article History

Received: 30 August 2021

Accepted: 15 November 2021

First Online: 5 January 2022

Competing interests

: SP, GA, CD, PG, ST, NC, M-AD’A, BJW, and NL are either employees of Medicago Inc. or receive salary support from Medicago Inc. NIRC, TNPRC, and Stanford University received payments or financial compensations from Medicago Inc. for the services they provided in this study. The other authors declare no competing interests.

Document is current

Any future updates will be listed below